secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001104659-26-006813
Event type: regulatory
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints
--------------------------------------------------------------------------------

- Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.
- Discussed clinically meaningful endpoints for proposed Phase 2b study in mild-to-moderate DLB.
- FDA meeting minutes expected later this quarter; no specific outcome disclosed.
- Zervimesine is an oral once-daily investigational drug targeting Aβ and α-synuclein toxicity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/0001104659-26-006813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465926006813/tm264096d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-006813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer